Anaptys Announces Participation in September Investor Conferences
Rhea-AI Summary
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics, has announced its participation in three upcoming investor conferences in September 2024:
1. 2024 Wells Fargo Healthcare Conference in Boston, MA on Sept. 5 at 10:15am ET
2. Stifel 2024 Virtual Immunology and Inflammation Summit on Sept. 17 at 1:30pm ET
3. 2024 Cantor Fitzgerald Global Healthcare Conference in New York, NY on Sept. 18 at 9:45am ET
The company's president and CEO, Daniel Faga, and/or other senior management team members will participate in fireside chats and one-on-one investor meetings. Live webcasts of the fireside chats will be available on the Anaptys website, with replays accessible for at least 30 days after the events.
Positive
- Participation in multiple high-profile investor conferences
- Opportunity for direct engagement with investors through one-on-one meetings
- Live webcasts of fireside chats available for broader investor access
Negative
- None.
News Market Reaction
On the day this news was published, ANAB declined 0.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
2024 Wells Fargo Healthcare Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Thursday, Sept. 5, 2024 at 10:15am ET / 7:15am PT
Stifel 2024 Virtual Immunology and Inflammation Summit
- Format – Fireside chat
- Date and Time – Tuesday, Sept. 17, 2024 at 1:30pm ET / 10:30am PT
2024 Cantor Fitzgerald Global Healthcare Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Sept. 18, 2024 at 9:45am ET / 6:45am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. It is developing immune cell modulators for autoimmune and inflammatory diseases, including two checkpoint agonists: ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis and rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. It also has other immune cell modulator candidates in its portfolio, including ANB033, an anti-CD122 antagonist antibody, entering a Phase 1 trial and ANB101, a BDCA2 modulator antibody, in preclinical development. In addition, Anaptys has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, that has completed Phase 3 trials for the treatment of generalized pustular psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3 ready. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including an anti-PD-1 antagonist antibody (Jemperli (dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
Contact:
Nick Montemarano
Senior Director, Investor Relations and Strategic Communications
858.732.0178
investors@anaptysbio.com
FAQ
What investor conferences will AnaptysBio (ANAB) attend in September 2024?
Who will represent AnaptysBio (ANAB) at the September 2024 investor conferences?
How can investors access AnaptysBio's (ANAB) presentations at the September 2024 conferences?
What type of company is AnaptysBio (ANAB)?
